These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 28703747)

  • 1. The Prostate Cancer Cells Resistant to Docetaxel as in vitro Model for Discovering MicroRNAs Predictive of the Onset of Docetaxel Resistance.
    Bascetta L; Oliviero A; D'Aurizio R; Evangelista M; Mercatanti A; Pellegrini M; Marrocolo F; Bracarda S; Rizzo M
    Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28703747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression.
    Corcoran C; Rani S; O'Driscoll L
    Prostate; 2014 Sep; 74(13):1320-34. PubMed ID: 25053345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA-223-3p regulates cell chemo-sensitivity by targeting FOXO3 in prostatic cancer.
    Feng Q; He P; Wang Y
    Gene; 2018 Jun; 658():152-158. PubMed ID: 29518547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucocorticoid receptor antagonism reverts docetaxel resistance in human prostate cancer.
    Kroon J; Puhr M; Buijs JT; van der Horst G; Hemmer DM; Marijt KA; Hwang MS; Masood M; Grimm S; Storm G; Metselaar JM; Meijer OC; Culig Z; van der Pluijm G
    Endocr Relat Cancer; 2016 Jan; 23(1):35-45. PubMed ID: 26483423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205.
    Puhr M; Hoefer J; Schäfer G; Erb HH; Oh SJ; Klocker H; Heidegger I; Neuwirt H; Culig Z
    Am J Pathol; 2012 Dec; 181(6):2188-201. PubMed ID: 23041061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA-195 regulates docetaxel resistance by targeting clusterin in prostate cancer.
    Ma X; Zou L; Li X; Chen Z; Lin Q; Wu X
    Biomed Pharmacother; 2018 Mar; 99():445-450. PubMed ID: 29665645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of docetaxel resistance genes in castration-resistant prostate cancer.
    Marín-Aguilera M; Codony-Servat J; Kalko SG; Fernández PL; Bermudo R; Buxo E; Ribal MJ; Gascón P; Mellado B
    Mol Cancer Ther; 2012 Feb; 11(2):329-39. PubMed ID: 22027694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of docetaxel resistance in prostate cancer: The key role played by miRNAs.
    Rizzo M
    Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188481. PubMed ID: 33217485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secreted miR-210-3p, miR-183-5p and miR-96-5p reduce sensitivity to docetaxel in prostate cancer cells.
    Canovai M; Evangelista M; Mercatanti A; D'Aurizio R; Pitto L; Marrocolo F; Casieri V; Pellegrini M; Lionetti V; Bracarda S; Rizzo M
    Cell Death Discov; 2023 Dec; 9(1):445. PubMed ID: 38065937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer.
    Lin HM; Castillo L; Mahon KL; Chiam K; Lee BY; Nguyen Q; Boyer MJ; Stockler MR; Pavlakis N; Marx G; Mallesara G; Gurney H; Clark SJ; Swarbrick A; Daly RJ; Horvath LG
    Br J Cancer; 2014 May; 110(10):2462-71. PubMed ID: 24714754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miRNA-34a is associated with docetaxel resistance in human breast cancer cells.
    Kastl L; Brown I; Schofield AC
    Breast Cancer Res Treat; 2012 Jan; 131(2):445-54. PubMed ID: 21399894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Ezh2 could overcome docetaxel resistance in prostate cancer cells.
    Qiu X; Wang W; Li B; Cheng B; Lin K; Bai J; Li H; Yang G
    BMC Cancer; 2019 Jan; 19(1):27. PubMed ID: 30621625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docetaxel-resistance in prostate cancer: evaluating associated phenotypic changes and potential for resistance transfer via exosomes.
    Corcoran C; Rani S; O'Brien K; O'Neill A; Prencipe M; Sheikh R; Webb G; McDermott R; Watson W; Crown J; O'Driscoll L
    PLoS One; 2012; 7(12):e50999. PubMed ID: 23251413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations.
    Li X; Wu JB; Chung LW; Huang WC
    Oncotarget; 2015 Dec; 6(38):41018-32. PubMed ID: 26512780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of SLC6A1 associates with drug resistance and poor prognosis in prostate cancer.
    Chen C; Cai Z; Zhuo Y; Xi M; Lin Z; Jiang F; Liu Z; Wan Y; Zheng Y; Li J; Zhou X; Zhu J; Zhong W
    BMC Cancer; 2020 Apr; 20(1):289. PubMed ID: 32252682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-200b suppresses cell proliferation, migration and enhances chemosensitivity in prostate cancer by regulating Bmi-1.
    Yu J; Lu Y; Cui D; Li E; Zhu Y; Zhao Y; Zhao F; Xia S
    Oncol Rep; 2014 Feb; 31(2):910-8. PubMed ID: 24317363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exosomes from bulk and stem cells from human prostate cancer have a differential microRNA content that contributes cooperatively over local and pre-metastatic niche.
    Sánchez CA; Andahur EI; Valenzuela R; Castellón EA; Fullá JA; Ramos CG; Triviño JC
    Oncotarget; 2016 Jan; 7(4):3993-4008. PubMed ID: 26675257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of lipidomic profiles associated with drug-resistant prostate cancer cells.
    Ingram LM; Finnerty MC; Mansoura M; Chou CW; Cummings BS
    Lipids Health Dis; 2021 Feb; 20(1):15. PubMed ID: 33596934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The UCA1/miR-204/Sirt1 axis modulates docetaxel sensitivity of prostate cancer cells.
    Wang X; Yang B; Ma B
    Cancer Chemother Pharmacol; 2016 Nov; 78(5):1025-1031. PubMed ID: 27686228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA in prostate cancer: Practical aspects.
    Patil PA; Magi-Galluzzi C
    Histol Histopathol; 2015 Dec; 30(12):1379-96. PubMed ID: 26186079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.